ERBB2 and triple-negative breast carcinoma: Entinostat, a histone deacetylase inhibitor used to treat various breast cancers, including HER2-positive and triple-negative breast cancer (Sidiropoulos et al., 2022; Trapani et al., 2017), was identified as a potential drug targeting CNIH4 using the Cmap database.